Goldman Sachs analyst David Roman raised the firm’s price target on Beta Bionics (BBNX) to $33 from $26 and keeps a Buy rating on the shares. Beta Bionics’ Q3 results underscore continued strength in the underlying diabetes market as well as the company’s market share gain trajectory, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBNX:
- Beta Bionics price target raised to $23 from $17 at Baird
- Beta Bionics price target raised to $32 from $26 at Piper Sandler
- Beta Bionics Reports Strong Q3 Growth and Raises Guidance
- Beta Bionics reports Q3 EPS (33c), consensus (41c)
- Beta Bionics raises FY25 revenue view to over $96.5M from $88M-$93M prior